---
title: "Hong Kong Stock Market Movement | Keji Pharmaceutical-B plunges more than 16%, with a 23-year loss of 748 million yuan, narrowing by 16.19% year-on-year"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/201925077.md"
description: "Koji Pharmaceutical-B plummeted by over 16%, closing at a 16.78% decrease to HKD 4.77 with a turnover of HKD 4.3 million. In terms of performance, as of the fiscal year ending December 31, 2023, the group incurred R&D expenses of RMB 662 million, a decrease of 2.74% year-on-year; shareholders' attributable loss was RMB 748 million, narrowing by 16.19% year-on-year; basic loss per share was RMB 1.34. The announcement stated that the main reason for the narrowing loss was the reduction in share-based compensation. Previously, the company announced that the board of directors declared that the summary of CT041 (a targeted Claudin18.2 autologous CAR-T cell candidate product) has been accepted for oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. It is reported that CT041 is a potential globally pioneering autologous CAR-T cell candidate product targeting the Claudin18.2 protein, used to treat Claudin18.2-positive solid tumors, mainly for the treatment of gastric/esophagogastric junction adenocarcinoma and pancreatic cancer"
datetime: "2024-04-15T02:01:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/201925077.md)
  - [en](https://longbridge.com/en/news/201925077.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/201925077.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/201925077.md) | [English](https://longbridge.com/en/news/201925077.md)


# Hong Kong Stock Market Movement | Keji Pharmaceutical-B plunges more than 16%, with a 23-year loss of 748 million yuan, narrowing by 16.19% year-on-year

According to the Zhitong Finance and Economics APP, Keji Pharmaceutical-B (02171) plummeted by over 16%, dropping by 16.78% to HKD 4.77 with a turnover of HKD 4.3 million as of the time of publication.

In terms of performance, for the fiscal year ending on December 31, 2023, the group incurred R&D expenses of RMB 662 million, a decrease of 2.74% year-on-year. Shareholders' attributable loss was RMB 748 million, narrowing by 16.19% year-on-year. Basic loss per share was RMB 1.34. The announcement stated that the main reason for the narrowing loss was the reduction in share-based compensation.

Previously, the company announced that the Board of Directors declared that the abstract of CT041 (a targeted Claudin18.2 autologous CAR-T cell candidate product) has been accepted for oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. It is reported that CT041 is a potential globally pioneering autologous CAR-T cell candidate product targeting the Claudin18.2 protein, used to treat Claudin18.2-positive solid tumors, primarily for the treatment of gastric/esophagogastric junction adenocarcinoma and pancreatic cancer

### 相關股票

- [CARSGEN-B (02171.HK)](https://longbridge.com/zh-HK/quote/02171.HK.md)

## 相關資訊與研究

- [Guotai Haitong Remains a Buy on Jinxin Fertility Group Ltd. (1951)](https://longbridge.com/zh-HK/news/281098586.md)
- [Sino Biopharmaceutical (OTCMKTS:SBMFF) Short Interest Update](https://longbridge.com/zh-HK/news/280904911.md)
- [Samsung Biologics labor union members have overwhelmingly voted in favor of strike, with 95.52% voting in favor on 95.38% turnout](https://longbridge.com/zh-HK/news/281030155.md)
- [JD.com's Ceconomy Takeover Faces Regulatory Uncertainty in Austria](https://longbridge.com/zh-HK/news/280964648.md)
- [SSY Group Wins China Approval for Upadacitinib Bulk Drug](https://longbridge.com/zh-HK/news/281103720.md)